Clinical Trial Update: L-CsA in the Prevention of Bronchiolitis Obliterans Syndrome (BOS) in Lung Transplant (LT) Patients [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/3 study evaluating liposomal cyclosporine A (L-CsA) to prevent bronchiolitis obliterans syndrome in lung transplant recipients has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bronchiolitis Obliterans Syndrome

Drugs mentioned

• L-CsA (liposomal cyclosporine A)

Snippet

Sponsor: Pari Pharma GmbH | Conditions: Bronchiolitis Obliterans | Phase 2, Phase 3 | Status: TERMINATED